Miao Pei-Dong, Li Ying, Jiang Yu-Dong
Dalian No.3 People's Hospital, Department of Interventional Radiology, Dalian, People's Republic of China.
Dalian 7th People's Hospital, Dalian, Liaoning Province, China.
Clin Transl Gastroenterol. 2024 Apr 1;15(4):e00690. doi: 10.14309/ctg.0000000000000690.
Hepatocellular carcinoma (HCC) remains a formidable oncological challenge, calling for innovative therapeutic strategies to improve patient outcomes. MicroRNAs have emerged as key regulators in cancer, and miR-3682-3p shows potential as a diagnostic and prognostic biomarker in HCC. We conducted a comprehensive study to uncover its role in HCC biology, revealing dysregulation and clinical associations. Target gene analysis provided insights into potential molecular mechanisms. Moreover, we explored its impact on the tumor microenvironment, immune cell infiltration, and therapy responses. Our findings highlight miR-3682-3p as a promising candidate for further investigations and potential therapeutic strategies in HCC management.
肝细胞癌(HCC)仍然是一个严峻的肿瘤学挑战,需要创新的治疗策略来改善患者的预后。微小RNA已成为癌症中的关键调节因子,而miR-3682-3p在HCC中显示出作为诊断和预后生物标志物的潜力。我们进行了一项全面的研究,以揭示其在HCC生物学中的作用,发现了其失调情况及临床关联。靶基因分析为潜在的分子机制提供了见解。此外,我们还探讨了其对肿瘤微环境、免疫细胞浸润和治疗反应的影响。我们的研究结果突出了miR-3682-3p作为HCC管理中进一步研究和潜在治疗策略的有前景的候选者。